Abstract 5769
Background
Information about chemotherapy is complex. Access to information prior to treatment enables patients to gain a better understanding of their condition, lessen their concerns and enables them to make informed choices about treatment. Traditionally chemotherapy education was provided by oncology clinical nurse specialists (CNS) on an individual basis to patients before they started chemotherapy. Increasing numbers of patients and reduced staff resources lead to problems maintaining service. The Irish Cancer Society’s Daffodil Centres are committed to quality improvement across cancer services available to those affected by cancer. Mater Misericordiae University Hospital (MMUH) and the Irish Cancer Society’s Daffodil Centre collaborated on a group chemotherapy initiative in 2012 initiated in response to a high demand for education services. After a successful pilot the programme is now running in 8 hospitals across Ireland. In 2018 342 group education sessions were held with 1713 attendees.
Methods
The Cancer Nurse in the Daffodil Centre facilitates this programme using educational tools including a specially produced audiovisual support (DVD) and short oral and practical demonstrations to assist different learning styles. To conclude the CNS meets with the patients to discuss their individual plan. All attendees are asked to complete an evaluation form which is inputted into a database and the results collated.
Results
1217 completed the evaluation out of 1713 attendees. A number of themes emerged including: • Welcoming • Good information • Allayed concerns • Empowerment. Acknowledgement of the expertise of the nurse and other allied healthcare professionals who present at the session – medical social workers and dietitians.
Conclusions
Overall satisfaction levels were very high in the programme including the information and content on the DVD and the information received and the way it was explained by the nurse. Of those who left comments they were very positive about the experience and for the opportunity to attend. By attending the session patients and their relative/friends were made to feel welcome. Their knowledge of chemotherapy and its side effects were greatly increased and their fears of commencing treatment were in many ways alleviated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract